Emla and Innohep drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Emla (lidocaine; prilocaine) and Innohep (tinzaparin sodium). Common drug interactions include bronchiolitis among females and cutaneous lupus erythematosus among males.

The phase IV clinical study analyzes what interactions people have when they take Emla and Innohep. It is created by eHealthMe based on reports of 34 people who take the same drugs from the FDA, and is updated regularly.

What is Emla?

Emla has active ingredients of lidocaine; prilocaine. eHealthMe is studying from 5,276 Emla users. Check the latest studies of Emla.

What is Innohep?

Innohep has active ingredients of tinzaparin sodium. eHealthMe is studying from 9,243 Innohep users. Check the latest studies of Innohep.

On Jul, 12, 2026

34 people who take Emla and Innohep together, and have interactions are studied.

What are the common drug interactions of Emla and Innohep, by gender? *:

female:

Bronchiolitis (inflammation of the membranes lining the bronchioles in lungs)
Decreased appetite
Dyspnoea (difficult or laboured respiration)
Melaena (the passage of black, tarry stools)
Nausea (feeling of having an urge to vomit)
Vomiting
Anaemia (lack of blood)
Dehydration (dryness resulting from the removal of water)
Diarrhoea
Hepatocellular injury (liver injury)

male:

Cutaneous lupus erythematosus (own immune system attacks various cells causing a wide variety of signs and symptoms)
Pyrexia (fever)
Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood)
Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood)
Liver disorder (liver diseases)
Renal failure (kidney dysfunction)
Systemic lupus erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue)
Nausea (feeling of having an urge to vomit)
Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)
Anastomotic ulcer

What are the common drug interactions of Emla and Innohep, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Pyrexia (fever)
Anastomotic ulcer
Haematochezia (passage of stools containing blood)
Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood)

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Diarrhoea
Melaena (the passage of black, tarry stools)
Nausea (feeling of having an urge to vomit)
Vomiting

60+:

Nausea (feeling of having an urge to vomit)
Cutaneous lupus erythematosus (own immune system attacks various cells causing a wide variety of signs and symptoms)
Hyperthermia (body temperature greatly above normal)
Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood)
Interstitial lung disease
Liver disorder (liver diseases)
Melaena (the passage of black, tarry stools)
Renal failure (kidney dysfunction)
Systemic lupus erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue)
Vomiting

What are the existing conditions these people have? *

Nausea (feeling of having an urge to vomit): 20 people, 58.82%
Depression: 18 people, 52.94%
Sleep Disorder: 17 people, 50.00%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 17 people, 50.00%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 17 people, 50.00%
Muscle Spasms (muscle contraction): 17 people, 50.00%
High Blood Pressure: 5 people, 14.71%
Diarrhea: 4 people, 11.76%
Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 3 people, 8.82%
Local Anaesthesia: 3 people, 8.82%

* Approximation only. Some reports may have incomplete information.

Do you take Emla and Innohep?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously